Trials / Completed
CompletedNCT02918539
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 317 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | florbetapir F 18 PET scan | For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-10-18
- Completion
- 2017-10-18
- First posted
- 2016-09-29
- Last updated
- 2018-10-24
Locations
75 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02918539. Inclusion in this directory is not an endorsement.